Search Results - carol feghali-bostwick

1 Results Sort By:
Antifibrotic effects of oxetanyl sulfoxides
Currently, there are only two approved therapies for Idiopathic Pulmonary Fibrosis (IPF), pirfenidone and nintedanib, which are minimally effective at slowing the disease. These treatments are not effective at all in halting or reversing the progression of IPF. Therefore, there remains a great need for more effective therapies. Researchers at MUSC ...
Published: 6/14/2017   |   Inventor(s): Carol Feghali-Bostwick, Peter Wipf
Keywords(s):  
Category(s): Therapeutic
© 2018. All Rights Reserved. Powered by Inteum